


CDK4/6-IN-8

Cat. No.:	HY-143258
CAS No.:	2649120-22-7
Molecular Formula:	C ₁₈ H ₁₈ N ₆ O ₅
Molecular Weight:	398.37
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CDK4/6-IN-8 (Compound 7p) is a selective CDK4 and CDK6 inhibitor with IC ₅₀ values of 5.01 nM and 3.97 nM, respectively ^[1] .									
IC₅₀ & Target	CDK6 3.97 nM (IC ₅₀)	CDK4 5.01 nM (IC ₅₀)								
In Vitro	<p>CDK4/6-IN-8 (Compound 7p) (0-656.1 μM, 48 h) shows anti-breast cancer activity^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7</td> </tr> <tr> <td>Concentration:</td> <td>0.1, 0.3, 0.9, 2.7, 8.1, 24.3, 72.9, 218.7 and 656.1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell viability with an IC₅₀ of 2.8 μM.</td> </tr> </table>		Cell Line:	MCF-7	Concentration:	0.1, 0.3, 0.9, 2.7, 8.1, 24.3, 72.9, 218.7 and 656.1 μM	Incubation Time:	48 h	Result:	Inhibited cell viability with an IC ₅₀ of 2.8 μM.
Cell Line:	MCF-7									
Concentration:	0.1, 0.3, 0.9, 2.7, 8.1, 24.3, 72.9, 218.7 and 656.1 μM									
Incubation Time:	48 h									
Result:	Inhibited cell viability with an IC ₅₀ of 2.8 μM.									

REFERENCES

[1]. Liang JW, et al. Synthesis and identification of a novel skeleton of N-(pyridin-3-yl) proline as a selective CDK4/6 inhibitor with anti-breast cancer activities. *Bioorg Chem.* 2022 Feb;119:105547.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA